Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More
by Zacks Equity Research
Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Exelixis (EXEL) Announces Final Results From HCC Study
by Zacks Equity Research
Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.
Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
by Indrajit Bandyopadhyay
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Exelixis (EXEL) Amends Agreement With Iconic Therapeutics
by Zacks Equity Research
Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors
by Zacks Equity Research
Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.
Exelixis (EXEL) Down 14.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
EXEL vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.
Exelixis (EXEL) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of -36.84% and -10.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
Is a Surprise Coming for Exelixis (EXEL) This Earnings Season?
by Zacks Equity Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.
Is a Beat in Store for Generac (GNRC) This Earnings Season?
by Zacks Equity Research
Generac's (GNRC) third-quarter 2021 earnings are likely to have been driven by a solid demand environment and effective acquisition strategies supported by a resilient business model.
Is a Beat in Store for T-Mobile (TMUS) This Earnings Season?
by Zacks Equity Research
T-Mobile's (TMUS) performance in the third quarter of 2021 is likely to have benefited from customer growth and 5G network expansion.